4D Molecular Therapeutics Inc. announced a corporate update and business outlook for 2026. As of December 31, 2025, the company reported $514 million in cash, cash equivalents, and marketable securities, which is expected to fund currently planned operations into the second half of 2028. The company noted progress in its 4D-150 program for wet age-related macular degeneration $(AMD)$, with enrollment in Phase 3 clinical trials exceeding expectations. Specifically, the 4FRONT-1 trial remains on track to complete enrollment in the first quarter of 2026, with 381 patients randomized or approved to randomize as of January 6, 2026. The target enrollment for the global Phase 3 program has been increased from 400 to 480 patients per trial to align with regulatory authorities and increase statistical power. Two-year Phase 2b PRISM data for 4D-150 in wet AMD is expected in mid-2026. For diabetic macular edema (DME), a global Phase 3 trial of 4D-150 is expected to begin in the third quarter of 2026, with two-year SPECTRA Phase 1/2 data anticipated in the second half of 2026. The company also reported ongoing preclinical development for 4D-725 in A1AT lung disease, which is fully funded by the California Institute for Regenerative Medicine. In addition, Glenn Sblendorio has joined the Board of Directors, bringing experience in commercial and operating roles in retina therapeutics. The company will present its strategic outlook at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621185) on January 07, 2026, and is solely responsible for the information contained therein.